₦ NGN
Language
Currency
‹ All headlines
ScienceDaily Health

Bowel cancer “melted away” after immunotherapy, then stayed away

2 weeks ago
A short course of immunotherapy before surgery may offer remarkably durable protection for some patients with stage two or three bowel cancer. In the NEOPRISM-CRC trial, 32 patients with a specific genetic form of bowel cancer received pembrolizumab for up to nine weeks before surgery instead of the usual post-surgery chemotherapy. After nearly three years of follow-up, none of the patients had ex...
Get the EPELCON App v3.6.0
Invest, Learn & Earn on the go
Download APK
feedback Feedback